With
Cysbiotic® Lallemand combines the
Benefits of Cranberry
and Probiotics in a single room-stable capsule
to support urogenital health
Up to 1 in 2 women with Urinary
Tract Infection experiences reoccurrence
within a year
Birker¯d,
Denmark - Blagnac, France, February 15th, 2010 - Lallemand
Health Ingredients (LHI) and Institut Rosell-Lallemand
(IR-L) announced today the launch of Cysbiotic®, a unique
womenís health dietary supplement that combines live
probiotic bacteria to a natural PAC-rich cranberry powder, to
create a room-stable capsule formula. This technological break-through
is the fruit of a long-term cooperation between probiotic expert
Institut Rosell-Lallemand and leading cranberry producer Decas
Botanical Synergies (DBS). Cysbiotic® is commercialised
by Lallemand which has exclusive license covering all countries.
Several launches of products containing Cysbiotic® are forecasted
in Europe before the summer through exclusive agreements with
pharmaceutical companies.
Building
on their combined expertise of cranberry and probiotics, the
research teams of DBS and IR-L have succeeded in overcoming
the technological challenge of preserving probiotic viability
in presence of cranberry, to develop a unique product. CysbioticÆ
combines Institut Rosellís well-documented Lactobacillus
rhamnosus Rosell-11 with Premium PAC standardised Whole Cranberry
Powder from DBS - PACranÆ, in a single capsule.
Nadine
Renard, Technical Manager for Lallemand explains: “it
has been a great challenge to find a formula that could guarantee
probiotics viability in presence of cranberry powder. The later
would normally kill live bacteria in the course of 2-3 months.
It is only thanks to Lallemandís expertise of live microorganisms
and unique technology that we have managed to develop a product
that is stable at room temperature for up to two years."
Nicolai
Jensen General Manager of Lallemand Health Ingredients remarks:
“At Lallemand, we are excited by the market possibilities
presented by this new all-in-one delivery system. By combining
our expertise in the probiotic and cranberry UTI segments, we
are proud to see this collaboration bear fruit!"
Urinary
Tract Infection (UTI) is the most common infection among women
and has a high reoccurrence rate. Its main causative agent is
E. Coli bacteria. Foxman et al. have shown that nearly 1 in
3 women will have had at least one episode of UTI requiring
antimicrobial therapy before they reach 24 years of age. Another
study estimates that nearly half of the women who have had a
UTI will experience another one within 12 months (Ik‰heimo
et al. 1996). UTIs are traditionally treated with antibiotics
but scientists believe that antibiotic treatments can disrupt
the natural occurrence of beneficial bacteria in the body, leading
to higher recurrence of UTI.
Furthermore,
repeated antibiotic treatments can give rise to antibiotic-resistant
strains of harmful bacteria.
Combining
the anti-adhesion power of cranberry...
Cranberries are widely documented for their preventive effect
against urinary tract infection, thanks to their unique anti-adhesion
activity. This activity is primarily due to the presence of
key phytochemicals: proanthocyanidines (PACs). PACs are present
in other plants, but cranberry have been shown to contain a
unique A-type PAC, while most other fruits contain only the
more common B-type PACs. Researchers have linked the presence
of A-type PAC in cranberry to its unique anti-adherence effect
against pathogenic bacteria.
Cysbiotic®
contains PACran®, made with PAC-rich Early
Black cranberries and standardised to a minimum 1.5% PACs, measured
via the HPLC analytical method. Its potential to support urinary
tract health has been demonstrated in a double-blind, randomised
clinical study in 2006. The daily consumption of 500 mg of PACran®
was able to significantly reduce the presence of uropathogenic
E. coli in patients. These results were supported by a recent
study performed at Rutgers University (New Jersey) on healthy
individuals, showing that the consumption of 500 mg PACranÆ
conferred the same level of ex vivo urinary anti-adhesion activity
against uropathogenic E. coli over a 24-hour period as 300 ml
of Cranberry Juice Cocktail.
...to
probiotics ìbarrier effectsî
It
has been shown that the oral administration of probiotic bacteria,
mainly Lactobacilli, can balance the gut and the vagina lactobacilli
microflora, both acting as natural barriers to protect the urinary
tract from uropathogens.
This
naturally occurring Lactobacilli flora in the gut helps prevent
colonisation by pathogenic bacteria, including E. coli. Moreover,
Lactobacilli represent an estimated 83% of the normal vaginal
microflora which protects the vaginal environment from the development
of harmful bacteria and forms a barrier to bladder entry by
uropathogens.
The
well documented strain Lactobacillus rhamnosus Rosell-11 has
been selected for the Cysbiotic® formulation. It shows good
resistance to gastric acidity and bile and has the ability to
bind to intestinal cell lines. It is already present in Institut
Rosellís finished product clinically documented against
bacterial vaginosis, currently sold under the brand name FermalacÆ
Vaginal.
By
combining PACran to Lactobacillus rhamnosus Rosell-11 probiotic
strain, Cysbiotic® could help support urinary tract health
through a dual action: Cranberriesí PACs hinder the uropathogens
adhesion to the urinary tract, while the beneficial bacteria
could help restore the gut and vaginal protective microflora
as well as limit the risks of pathogens development, leading
to better urinary tract health.
Cysbiotic®
is offered in a capsule form containing 250 mg PACran and 0.5
billion L. rhamnosus Rosell-11. Two capsules per day will deliver
the recommended daily amount of PACran and one billion probiotic
bacteria. Its shelf-life is supported by stability data for
24 months at room temperature, under normal conditions (25∞C
and 40 % HR).